Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 11/20 | 0.76 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.76 |
| ▸ | HTR1A | P08908 | 5/20 | 0.56 |
| ▸ | TSPO | P30536 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 5/20 | 0.43 |
| ▸ | DRD3 | P35462 | 5/20 | 0.43 |
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949001 | 0.88 | HCRTR2 (0.58) | HCRTR2HCRTR1HTR1A | |
| SCHEMBL9948757 | 0.87 | HCRTR2 (0.73) | HCRTR2HCRTR1HTR1ATSPO | |
| SCHEMBL9949156 | 0.85 | HCRTR2 (0.63) | HCRTR2HCRTR1HTR1ATSPO | |
| SCHEMBL9948732 | 0.85 | HCRTR1 (0.55) | HCRTR2HCRTR1HTR1A | |
| SCHEMBL9948734 | 0.84 | HCRTR2 (0.75) | HCRTR2HCRTR1HTR1ATSPODRD2 | |
| SCHEMBL9949089 | 0.81 | HCRTR2 (0.62) | HCRTR2HCRTR1HTR1ATSPO | |
| SCHEMBL9948976 | 0.79 | HCRTR2 (0.71) | HCRTR2HCRTR1HTR1ATSPO | |
| SCHEMBL9948608 | 0.78 | HCRTR2 (0.54) | HCRTR2HCRTR1HTR1ATSPO | |
| SCHEMBL2133545 | 0.78 | HCRTR2 (0.82) | HCRTR2HCRTR1HTR1ATSPO | |
| SCHEMBL9948764 | 0.78 | HCRTR2 (0.74) | HCRTR2HCRTR1HTR1ATSPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | claimed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | claimed |
| WO-2012101487-A1 | DI/TRI-AZA-SPIRO-C9-C11ALKANES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165331-A1 | Di/tri-aza-spiro-C9-C11alkanes | TACR2, TACR1, AGTR1 | HCRTR2 607/4885HCRTR1 593/4885HTR1A 855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.